Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 22;2(1):vdz055. doi: 10.1093/noajnl/vdz055

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 3 — ICG-001 disrupts the interaction between β-catenin and CBP and robustly induces G1 arrest in meningioma cells in vitro. (A) The interaction between CBP and β-catenin was disrupted in CH157-MN and IOMM-Lee cells by 5 μM ICG-001 treatment for 12 hours as measured with coimmunoprecipitation. (B) A heat map of a core set in CH157-MN and IOMM-Lee cells treated with 5 μM ICG-001 at 8 and 24 hours, respectively. (C) mRNA levels for genes link to cell cycle after treatment with ICG-001. P values are derived from Wald test statistics in the DESeq2 package. (D) EdU assay shows CH157-MN and IOMM-Lee cells treated with ICG-001 at 5 μM resulted in a significantly decrease in proliferation (n = 3, P < .001). (E) ICG-001 treatment robustly induced G1 arrest in CH157-MN and IOMM-Lee cells (n = 3 for each dose, P values depict differences as dose-dependent manner). (F) Western blot revealed corresponding increased p21 and decreased survivin protein expression within 4 to 24 hours following ICG-001 treatment.